Literature DB >> 33166409

Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

Yuko Suzuki1, Hideto Sano1, Liina Mochizuki1, Naoki Honkura1, Tetsumei Urano1.   

Abstract

Our previous real-time imaging studies directly demonstrated the spatiotemporal regulation of clot formation and lysis by activated platelets. In addition to their procoagulant functions, platelets enhanced profibrinolytic potential by augmenting the accumulation of tissue-type plasminogen activator (tPA) and plasminogen, in vivo in a murine microthrombus model, and in vitro in a platelet-containing plasma clot model. To clarify the role of thrombin-activatable fibrinolysis inhibitor (TAFI), which regulates coagulation-dependent anti-fibrinolytic potential, we analyzed tPA-induced clot lysis times in platelet-containing plasma. Platelets prolonged clot lysis times in a concentration-dependent manner, which were successfully abolished by a thrombomodulin-neutralizing antibody or an activated TAFI inhibitor (TAFIaI). The results obtained using TAFI- or factor XIII-deficient plasma suggested that TAFI in plasma, but not in platelets, was essential for this prolongation, though its cross-linkage with fibrin was not necessary. Confocal laser scanning microscopy revealed that fluorescence-labeled plasminogen accumulated on activated platelet surfaces and propagated to the periphery, similar to the propagation of fibrinolysis. Plasminogen accumulation and propagation were both enhanced by TAFIaI, but only accumulation was enhanced by thrombomodulin-neutralizing antibody. Labeled TAFI also accumulated on both fibrin fibers and activated platelet surfaces, which were Lys-binding-site-dependent and Lys-binding-site-independent, respectively. Finally, TAFIaI significantly prolonged the occlusion times of tPA-containing whole blood in a microchip-based flow chamber system, suggesting that TAFI attenuated the tPA-dependent prolongation of clot formation under flow. Thus, activated platelet surfaces are targeted by plasma TAFI, to attenuate plasminogen accumulation and fibrinolysis, which may contribute to thrombogenicity under flow.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33166409      PMCID: PMC7656914          DOI: 10.1182/bloodadvances.2020002923

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  50 in total

1.  The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.

Authors:  C Carrieri; R Galasso; F Semeraro; C T Ammollo; N Semeraro; M Colucci
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

2.  Activation of human neo-plasminogen-Val442 by urokinase and streptokinase and a kinetic characterization of neoplasmin-Val442.

Authors:  J R Powell; F J Castellino
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

3.  The presence and release of alpha 2-antiplasmin from human platelets.

Authors:  E F Plow; D Collen
Journal:  Blood       Date:  1981-12       Impact factor: 22.113

Review 4.  Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.

Authors:  T Plug; J C M Meijers
Journal:  J Thromb Haemost       Date:  2016-03-30       Impact factor: 5.824

5.  TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.

Authors:  N J Mutch; L Thomas; N R Moore; K M Lisiak; N A Booth
Journal:  J Thromb Haemost       Date:  2007-02-02       Impact factor: 5.824

6.  Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets.

Authors:  Laurent O Mosnier; Paula Buijtenhuijs; Pauline F Marx; Joost C M Meijers; Bonno N Bouma
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

7.  Real-time analysis of platelet aggregation and procoagulant activity during thrombus formation in vivo.

Authors:  Tadataka Hayashi; Hideo Mogami; Yusuke Murakami; Toshio Nakamura; Naohiro Kanayama; Hiroyuki Konno; Tetsumei Urano
Journal:  Pflugers Arch       Date:  2008-06-14       Impact factor: 3.657

Review 8.  Platelet-Mediated Modulation of Fibrinolysis.

Authors:  Claire S Whyte; Joanne L Mitchell; Nicola J Mutch
Journal:  Semin Thromb Hemost       Date:  2017-02-19       Impact factor: 4.180

9.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.

Authors:  Ran Ni; Miguel A D Neves; Chengliang Wu; Samantha E Cerroni; Matthew J Flick; Heyu Ni; Jeffrey I Weitz; Peter L Gross; Paul Y Kim
Journal:  J Thromb Haemost       Date:  2020-09       Impact factor: 5.824

10.  Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta.

Authors:  I Maruyama; C E Bell; P W Majerus
Journal:  J Cell Biol       Date:  1985-08       Impact factor: 10.539

View more
  5 in total

Review 1.  Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications.

Authors:  Filomena Napolitano; Nunzia Montuori
Journal:  Int J Mol Sci       Date:  2022-05-28       Impact factor: 6.208

Review 2.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

3.  Assessment of histological characteristics, imaging markers, and rt-PA susceptibility of ex vivo venous thrombi.

Authors:  Samuel A Hendley; Alexey Dimov; Aarushi Bhargava; Erin Snoddy; Daniel Mansour; Rana O Afifi; Geoffrey D Wool; Yuanyuan Zha; Steffen Sammet; Zheng Feng Lu; Osman Ahmed; Jonathan D Paul; Kenneth B Bader
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

4.  Group A Streptococcus-Induced Activation of Human Plasminogen Is Required for Keratinocyte Wound Retraction and Rapid Clot Dissolution.

Authors:  Henry M Vu; Daniel E Hammers; Zhong Liang; Gabrielle L Nguyen; Mary E Benz; Thomas E Moran; Dustin L Higashi; Claudia J Park; Yetunde A Ayinuola; Deborah L Donahue; Ana L Flores-Mireles; Victoria A Ploplis; Francis J Castellino; Shaun W Lee
Journal:  Front Cardiovasc Med       Date:  2021-06-10

5.  Blood Pumps for Extracorporeal Membrane Oxygenation: Platelet Activation During Different Operating Conditions.

Authors:  Francesco Fiusco; Lars Mikael Broman; Lisa Prahl Wittberg
Journal:  ASAIO J       Date:  2022-01-01       Impact factor: 2.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.